Cargando…

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

BACKGROUND: A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations in exon 19 or 21. METHODS: Eligible patients were randomised to receive erlotinib (150 mg pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C, Jiang, B Y, Bai, X Y, Zhong, W Z, Yang, X N, Wu, Y L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344291/ https://www.ncbi.nlm.nih.gov/pubmed/28103612 http://dx.doi.org/10.1038/bjc.2016.456

Ejemplares similares

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
por: Chen, R.-L., et al.
Publicado: (2017)

Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer
por: Yang, R.F., et al.
Publicado: (2017)

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
por: Wang, Y, et al.
Publicado: (2014)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer
por: Yang, X., et al.
Publicado: (2022)

Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double‐blind, phase III study
por: Yang, L.Q., et al.
Publicado: (2017)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
por: AlRasheed, Hajer, et al.
Publicado: (2022)

A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women
por: Shen, S, et al.
Publicado: (2015)

Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Xu, J. L., et al.
Publicado: (2015)

Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery
por: Yan, D-W, et al.
Publicado: (2010)

MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis
por: Li, Y-L, et al.
Publicado: (2017)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
por: Wang, Debby D., et al.
Publicado: (2015)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
por: Zou, Bin, et al.
Publicado: (2018)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury
por: Li, J-X, et al.
Publicado: (2014)

Different amino acid supplementation patterns in low-protein diets on growth performance and nitrogen metabolism of goslings from 1 to 28 days of age
por: Liang, Y.Q., et al.
Publicado: (2022)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma
por: Zhang, J., et al.
Publicado: (2017)

Prevalence of pollen‐induced allergic rhinitis with high pollen exposure in grasslands of northern China
por: Wang, X.‐Y., et al.
Publicado: (2018)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Remote magnetic navigation vs. manual navigation for ablation of ventricular tachycardia: a meta-analysis
por: Wu, Y., et al.
Publicado: (2015)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia
por: Weng, X-Q, et al.
Publicado: (2013)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo
por: Gao, Y, et al.
Publicado: (2015)

catena-Poly[[(1,10-phenanthroline-κ(2) N,N′)praseodymium(III)]-di-μ-phenoxyacetato-κ(4) O:O′-[(1,10-phenanthroline-κ(2) N,N′)praseodymium(III)]-di-μ-phenoxyacetato-κ(4) O:O′-di-μ-phenoxyacetato-κ(3) O,O′:O;κ(3) O:O,O′]
por: Zhong, H., et al.
Publicado: (2008)

Autophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis
por: Li, J, et al.
Publicado: (2017)

Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study
por: Zheng, X., et al.
Publicado: (2021)

Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
por: Li, J., et al.
Publicado: (2022)

S234: CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION
por: Shang, Q.-N., et al.
Publicado: (2022)

Retraction of articles by H. Zhong et al.
por: Zhong, H., et al.
Publicado: (2009)

Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series
por: Qian, G -Q, et al.
Publicado: (2020)

Dentinal mineralization is not limited in the mineralization front but occurs along with the entire odontoblast process
por: Li, C., et al.
Publicado: (2018)

P1655: PERSONALIZED MACHINE-LEARNING-BASED PREDICTION FOR CRITICAL IMMUNE THROMBOCYTOPENIA BLEEDS: A NATIONWIDE DATA STUDY
por: An, Z.-Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r5648dveue6bskn8it80up1b1j